Apex Biotechnology Ownership

1733 Stock  TWD 30.90  0.10  0.32%   
Apex Biotechnology holds a total of 99.95 Million outstanding shares. Apex Biotechnology Corp shows 15.5 percent of its outstanding shares held by insiders and 2.52 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Apex Stock Ownership Analysis

About 16.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.46. In the past many companies with similar price-to-book ratios have beat the market. Apex Biotechnology Corp last dividend was issued on the 16th of June 2022. The entity had 1:1 split on the 1st of July 2009. Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of medical devices by using biosensor technology worldwide. Apex Biotechnology Corp. was founded in 1997 and is headquartered in Hsinchu, Taiwan. APEX BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange. For more info on Apex Biotechnology Corp please contact Thomas Shen at 886 3 564 1952 or go to https://www.apexbio.com.

Apex Biotechnology Outstanding Bonds

Apex Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Apex Biotechnology Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Apex bonds can be classified according to their maturity, which is the date when Apex Biotechnology Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Apex Stock Analysis

When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.